Comment on: Possible miliary tuberculosis during adalimumab therapy with negative g-IFN release assays: reply SIR, We would like to thank Mangat et al.
[1] for their interest in our article [2] and would like to make the following comments.
We did not isolate any organisms including non-tuberculous mycobacterium (NTM) from sputum or bronchoalveolar lavage fluid. NTM infection is rare in the immunocompromised patient with otherwise structurally normal lungs, more frequently affecting those with chronic lung disease such as chronic obstructive pulmonary disease or bronchiectasis (which was not present in this patient). NTM are also ubiquitous throughout the environment [3] and identification of these organisms, particularly if confined to a positive mycobacterium PCR, would not necessarily confirm these as the causative organism even in the absence of tuberculous mycobacterium. We agree, however, that a positive PCR result for Mycobacterium tuberculosis (MT) would have been of interest, but it was not locally available. Because of rapid deterioration in an immunocompromised patient, the decision to treat empirically for tuberculosis was essentially made on clinical grounds. The patient did not develop significant evidence of side effects (e.g. liver toxicity) and, hence, in the absence of microbiological confirmation, risks of inadequate treatment outweighed the risks of continuing treatment.
If this case does in fact represent NTM infection then these opportunistic organisms may potentially cause significant disease in patients treated with anti-TNF. Duration of treatment in NTM is often longer than for MT, however; in this case, the cause of immunosuppression was withdrawn. The patient was followed up during and after the completion of treatment and has not suffered relapse.
We would agree with Mangat et al. that an ELISPOT test is potentially more informative in immunocompromised patients. Our patient did have this test prior to commencing anti-TNF therapy as part of the RHAPSODY trial protocol, but it was not available locally when she became unwell. From the limited headto-head comparison data available, the pooled sensitivity of TB-SPOT-TB, while greater than QuantiFERON Gold, is still not complete. Recent national guidelines for tuberculosis diagnosis [4] and an NHS Health Technology Assessment [5] have reviewed the use of -IFN assays in latent tuberculosis and briefly considered the use of -IFN release assays to rule out active infection. Caution should be exercised for both MT and NTM infection in the immunocompromised patient. The current national guidelines for assessing risk and managing MT infection in patients who are due to start anti-TNF therapy do not yet consider these issues [6] . SIR, We note with great interest the recent guideline from the BSR regarding the long-term management of RA [1]. Our comment refers to guideline 2 which states that, although randomized controlled trails of aggressive treatment regimes suggest that remission rates remain high and radiographic progression is slow, the withdrawal or reduction of DMARD therapy in the hope of achieving drug-free remission is not justified and therefore not recommended.
This suggests that the recommendation is to escalate DMARDs rapidly in an endeavour to achieve tight control and aim for remission, without recourse to stopping DMARDs, reducing the number of drugs or the dose once remission is achieved for any length of time. The recommendation is justified on the basis of two previous studies from the 1990s [2, 3] (a time at which the management of RA could be considered to be considerably less aggressive and DMARDs initiated later in the disease course than current practice). It is also noteworthy that the authors of the second RCT conclude that 62% of the placebo (withdrawn from DMARD) group went 12 months without experiencing a flare and that some patients may take a chance and decide to take a treatment break rather that continue indefinitely.
This issue was recently reviewed in a meta-analysis performed by O'Mahony et al. [4] . The studies involving traditional DMARDs were all >10 years old and many used third-line DMARDs such as penicillamine, gold and azathioprine. The majority abruptly discontinued the DMARD replacing with placebo as opposed to a gradual reduction. There is only a single case series looking at reducing the dose of MTX, albeit going from weekly to fortnightly. However, this study showed that 87% of the RA patients remained stable despite halving the dose [5] .
We would urge caution in interpreting the limited data available. In truth we simply do not know the risks of reducing the numbers and doses of DMARDs given in current treatment regimes, with early intervention (including the treatment of those with undifferentiated inflammatory arthritis), use of multiple DMARDs and escalating to high dose quickly. We also do not really know the long-term risks of adverse events of such aggressive management. The ultimate goal of remission without drugs may be possible for some given the modern approach and drug holidays may be possible for others. If a patient requests a reduction in therapy they should be made aware of the possibility
